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ABSTRACT 
Objective 
Although aminosalicylic acid (ASA) preparations have been used as first-line 
drugs for the treatment of Ulcerative colitis (UC), no consistent view has been 
established regarding the ASA dose during the remission-maintenance phase of 
the disease. In this study, we examined whether the ASA dose should be reduced 
during the remission-maintenance phase. 
Materials and methods 
This study included 203 patients in the remission-maintenance phase of UC. The 
Mayo endoscopic subscore (MES) was used to evaluate mucosa. Comparison and 
analysis were performed between patients whose ASA dose had been unchanged 
and whose dose had been reduced, between patients with endoscopic healing (EH) 
group and those without endoscopic healing (WEH) group, and between patients 
with an MES of 0 and 1. 
Results 
Comparison between the unchanged-ASA and reduced-ASA groups revealed that 
the remission-maintenance rate was higher in the unchanged-ASA group (P  
0.001). Next, the remission-maintenance rate was higher in the 
EH/unchanged-ASA group than in the EH/reduced-ASA group (P  0.042). 
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Comparison between the MES 0 and MES 1 groups revealed that the 
remission-maintenance rate was higher in the MES 0 group (P  0.007).In 
addition, no significant difference in remission-maintenance rates was observed 
between the MES 0/unchanged-ASA group and the MES 0/reduced-ASA group (P 
 0.108). 
Conclusions 
When the same ASA dose is maintained regardless of the presence or absence of 
EH, remission is more likely to be maintained. If the ASA dose must be reduced, 
dose reduction is more advantageous after an MES of 0 is achieved. 
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INTRODUCTION 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown 
etiology that is localized to colonic mucosa. The disease manifests with clinical 
symptoms such as abdominal pain, diarrhea, and bloody stool, and is 
characterized by a cycle of relapse and remission. While no fundamental 
therapeutic strategy has been established, the therapeutic goals are to achieve 
remission by suppressing symptoms such as abdominal pain and bloody stool, and 
to maintain remission [1]. 
Aminosalicylic acid (ASA) preparations are thought to act on colonic mucosa and 
to suppress inflammation in UC. These preparations have been used for the 
treatment of UC for a long period [2]. Several previous studies have shown that in 
patients with mild-to-moderate UC, remission-induction and 
remission-maintenance rates were higher in those patients receiving ASA than in 
those patients receiving placebo. Unlike corticosteroids and immunomodulators 
(IMs), the difference in the incidence of adverse reactions was not significant 
between the ASA and placebo groups, and ASA is used as a first-line drug for the 
treatment of UC [3-5]. Previous studies have shown that remission-maintenance 
rates are higher with higher ASA doses and better adherence [6]. However, high 
oral doses lead to poor adherence in patients, and long-term treatment with a 
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high dose increases medical costs. So, reductions in ASA dose need be considered 
possible. However, at present, there has been no consistent view on the criteria 
for reduction of the ASA dose. 
In recent years, studies have shown that achievement of mucosal healing (MH) in 
patients with UC leads to reduced rates of relapse and hospitalization, as well as 
fewer surgeries for colorectal cancer and other conditions [7-9]. A view that 
therapeutic goals should be set for achieving not only clinical remission but also 
MH has been widely accepted [10]. However, no consistent view has been 
established regarding ASA doses after achievement of MH. 
In this study, we retrospectively investigated whether ASA doses could be reduced 
in patients with UC in the remission-maintenance phase. We also examined 
whether endoscopic healing (EH) could serve as a rationale for reduction of ASA 
dose. 
 
 
MATERIALS AND METHOD 
Patients 
This study targeted patients with UC who have maintained remission for at least 
one year with 5-ASA alone or combination use of 5-ASA and IM, had undergone 
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colonoscopy of the mucosa, and had showed good adherence (defined as taking 
80% of prescribed doses according to medical records) during regular visits to 
Dokkyo Medical University Hospital or Japanese Red Cross Ashikaga Hospital 
between January 2008 and December 2014. Among patients concomitantly 
receiving IM, those receiving IM at a constant dose during the follow-up period 
were included. Clinical remission was defined as a clinical activity index (CAI) 
[11] of 4 or below. The scores of CAI were retrospectively calculated, based on the 
data drawn from the medical records. We selected 207 patients who received a 
constant dose of ASA for at least one year or whose ASA dosage was reduced 
during this follow-up period for the study.  
An ASA dose of 3600 mg or more per day in mesalazine equivalent was considered 
a high dose, and that less than this dose was regarded as a low dose. Specifically, 
the high dose was 4000 mg per day of time-dependent ASA (Pentasa, Kyorin 
Pharmaceutical Co., Ltd) and 3600 mg per day of pH-dependent ASA (Asacol, 
Zeria Pharmaceutical Co., Ltd.). In patients receiving salazosulfapyridine 
(Salazopyrin, Pfizer Japan Inc.), all doses were considered low doses because 
the salazosulfapyridine doses expressed in ASA equivalent were lower than the 
doses of the two drugs described above. Dose reduction of 5-ASA was considered 
for patients who had been in clinical remission for at least one year based on 
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endoscopic findings. 
This study has been approved by the ethics committee of Dokkyo Medical 
University. 
 
Endoscopic findings and endoscopic healing 
The Mayo endoscopic subscore (MES) [12] was used for endoscopic evaluation of 
mucosa, and an MES of 0 or 1 was considered to indicate EH. Endoscopic findings 
were evaluated by three endoscopists specialized in the treatment of 
inflammatory bowel disease. The images on the display of the computer were 
viewed by endoscopists who were blinded to the clinical data, and scores agreed 
upon by at least two of the endoscopists were used for analysis. Scores obtained 
from the sections of the large intestine (the cecum, ascending colon, transverse 
colon, descending colon, sigmoid colon, and rectum) with the most severe 
inflammation were used. Thus, endoscopic assessment was based on validation of 
endoscopic pictures. After four patients with multiple sections of large intestine 
scored as MES 1 and 2 were excluded, a total of 203 patients were considered to 
be eligible for analysis. Table I shows characteristics of these patients. The 
majority of patients had pancolitis type. There were 176 patients whose mucosa 
was evaluated as MES 0 or 1. 
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Moreover, in order to investigate whether differences existed between patients 
with an MES of 0 and an MES of 1, we selected patients whose mucosa was 
evaluated as MES 0 or 1 by all three endoscopists. Of the 176 patients, 120 were 
assigned the same score by the endoscopists. These patients included 96 patients 
with an MES of 0 and 24 patients with an MES of 1 (Figure 1). These patient 
groups were then compared and analyzed. 
 
Data analysis 
First, the patients were divided into two groups for comparison and analysis: 
those whose ASA dose remained unchanged and those whose ASA dose was 
reduced. Next, the patients were divided into those with or without EH for 
comparison and analysis. Furthermore, the patients with EH were divided into 
those with MES 0 or 1 for comparison and analysis. In addition, age, sex, disease 
duration, lesion range, concomitant use of IM, and history of hospitalization were 
also analyzed to investigate whether there were risk factors likely to cause 
relapse. 
 
Statistical analysis 
Statistical analysis was performed with statistics software (IBM SPSS Statistics 
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21, IBM Japan, Ltd.). For comparison of remission-maintenance rates, survival 
curves were generated by Kaplan-Meier method and log-rank test was performed. 
Student’s t test was used to analyze age and disease duration. While the 2 test 
was used for comparison by sex, use of IM, and history of hospitalization, Fisher’s 
exact test was used for variables with an expected value of 5 or less. A P value of 
less than 0.05 was considered to indicate statistical significance. 
 
 
RESULT 
Comparison with continuation and reduction of the ASA dose 
Patient characteristics in the unchanged-ASA and reduced-ASA groups are 
shown in Table II. First, comparison and analysis between these groups revealed 
that the remission-maintenance rate was statistically significantly higher in the 
unchanged-ASA group (P  0.001) (Figure 2). Then, after the unchanged-ASA 
group was divided into patients receiving the high dose of ASA (HD group) and 
those receiving the low dose of ASA (LD group) for analysis, the 
remission-maintenance rate was significantly higher in the LD group, as 
compared with that in the reduced-ASA group (P  0.001). The HD group showed 
higher remission-maintenance rates than the reduced-ASA group, but the 
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difference did not reach statistical significance (P  0.092) (Figure 3). 
 
Relationship of endoscopic healing and ASA dose 
The unchanged-ASA and reduced-ASA groups were combined and then divided 
into patients with EH group and those without endoscopic healing (WEH) group 
for analysis. The EH group included 176 patients, and the WEH group included 
29 patients. These groups were compared and analyzed. The EH group showed 
significantly higher remission-maintenance rates, as compared to the WEH group 
(P  0.020) (Figure 4). When the unchanged-ASA and reduced-ASA groups were 
separately divided into 4 groups according to EH status for analysis, a significant 
difference in the remission-maintenance rates was observed between the 
EH/unchanged-ASA group and the EH/reduced-ASA group (P  0.042) (Figure 5). 
Meanwhile, when the EH/unchanged-ASA group and the WEH/unchanged-ASA 
group were compared, no significant difference was observed in the 
remission-maintenance rates (P  0.245). The WEH/reduced-ASA group included 
only 4 patients, all of whom experienced relapse. 
 
Comparison with MES 0 and MES 1 
The patients with an MES of 0 or 1 were analyzed for remission rates. The 
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patient characteristics of the MES 0 and MES 1 groups are shown in Table III. 
When we examined whether the remission-maintenance rates differed between 
these groups, a statistically significant difference was observed (P  0.007). 
Furthermore, each of these groups was divided by ASA dose, and the resulting 
four groups were analyzed (Figure 6). No statistically significant difference was 
observed between the MES 0/unchanged-ASA and MES 1/unchanged- ASA groups 
(P  0.108). Moreover, comparison between the MES 0/unchanged-ASA and MES 
0/reduced- ASA group did not show any statistically significant difference (P  
0.111). The MES 1/reduced-ASA group included only 4 patients, half of whom 
experienced relapse during the follow-up period. 
 
Risk factor 
Patients with EH or MES 0 were divided into two groups according to the 
presence or absence of relapse for comparison. No difference was observed in age, 
sex, disease duration, lesion range, presence or absence of concomitant use of IM, 
or presence or absence of history of hospitalization. 
 
 
DISCUSSION 
  
 
12 
 
Earlier studies have shown that in the treatment of mildly or moderately active 
UC, high ASA doses led to higher rates of inducing remission or achieving EH, 
compared to low doses [12-15]. However, there has been no consistent view on the 
determination of ASA doses for UC in the remission-maintenance phase. 
Our study showed that relapse rates were higher in patients with UC in the 
remission-maintenance phase whose ASA dose had been reduced than in those 
whose ASA dose had remained unchanged, suggesting that ASA dose should not 
be reduced on the basis of only clinical remission. Regarding the reasons for the 
higher remission-maintenance rates in the LD group than in HD group, we 
speculate that there may have been a selection bias that caused the HD group to 
include more patients with initial highly active disease, resulting in more 
patients consequently experienced relapse in the HD group. 
Moreover, in recent years, EH has been recommended as a goal in the treatment 
of UC. In a workshop of the European Crohn’s and Colitis Organization (ECCO), 
EH was indicated to be helpful [16]. This is mainly attributed to earlier studies 
showing that EH reduces the incidence rate of colorectal cancer [7-9], relapse rate 
[17,18], and the like. Particularly, histological stimulation due to severe 
inflammation or chronic persistent inflammation has been implicated as a major 
risk factor for the development of colorectal cancer [7,19]. 
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According to an article summarizing the ASCEND (Assessing the Safety and 
Clinical Efficacy of a New Dose of 5-ASA) I and II trials, comparison between 
patients with moderately active UC who received pH-dependent ASA at a dose of 
4.8 g per day and those who received the drug at a dose of 2.4 g per day revealed 
that the proportion of patients achieving EH after 6 weeks of treatment was 
higher in the former [20]. In patients with mildly active UC, the proportion of 
those achieving EH was high in either dose, showing no significant difference. In 
consideration of these findings together with our results, we recommend high 
ASA doses to achieve EH. 
Regarding the association between EH and ASA doses, as with an earlier study 
[10], our study also revealed that the remission-maintenance rate was 
significantly higher in the EH group. However, the rate in the EH/reduced-ASA 
group was significantly lower than that in the EH/unchanged-ASA group. 
Although the WEH/reduced-ASA group included only 4 patients, relapse was 
observed in all of them. Thus, it seems that ASA doses should not be reduced 
when EH is not observed. When comparing the EH/unchanged-ASA and 
WEH/unchanged-ASA groups, no significant difference was observed in 
remission-maintenance rates. This indicated that remission could be maintained 
by keeping ASA doses unchanged even in patients WEH. According to these 
  
 
14 
 
results, when an MES of 0 or 1 is considered to indicate EH, reduction of ASA 
dose may not be recommended even in patients with EH. 
While EH is defined as an MES of 0 or as an MES of 0 or 1 in previous studies 
[13,17,21], we defined EH as an MES of 0 or 1 in our study. Comparing patients 
with an MES of 0 and an MES of 1, Meucci et al [17]reported no difference in 
remission-maintenance rates, whereas Nakarai et al [22] reported that the rates 
were significantly higher in patients with MES 0 in agreement with our study. 
The disagreement between the results of these studies may be attributable to 
differences in study designs. The study conducted by Meucci et al included only 
patients who achieved clinical remission after 6 weeks of consecutive 
administration of 4 g of oral mesalazine and 2 g of transanal mesalazine, and 
these patients were prospectively followed for up to one year. On the other hand, 
the study conducted by Nakarai et al is a retrospective study with 6 years of 
follow-up that had no exclusion criteria regarding treatments for patients. 
Moreover, our study included only four patients with an MES of 1 who received 
reduced ASA dosage, and two of them experienced relapse. These results indicate 
that there is a difference between conditions evaluated as MES 0 or MES 1, which 
are frequently considered to indicate EH. It is assumed that ASA doses should be 
reduced after MES is lowered to 0. In addition, a previous study has shown that 
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patients with an MES of 0 account for approximately 55% of patients with clinical 
remission, while the remaining 45% have inflammatory mucosa evaluated as 
MES 1 or above [23]. Endoscopic evaluation may be required as needed. 
In recommending EH as a therapeutic goal, the lack of an established definition 
of EH is a problem. Although there are currently many studies in which an MES 
of 0 or 1 are considered to indicate EH, our study revealed a difference in relapse 
rates between patients with MES 0 and MES 1. So, it is required that specific 
standards will be established for the term of EH in the future. 
In this study, we investigated risk factors for relapse in patients with UC, 
considering the presence of a history of hospitalization to be an indication that a 
patient had experienced severe relapse. As a result, none of the variables that we 
analyzed was identified as a risk factor for causing relapse. 
This study has the following limitations: First, because the severity of 
inflammation in the active phase and the methods used to induce remission were 
not determined, this study might have included patients who were more likely to 
experience relapse. Second, time-dependent ASA, pH-dependent ASA, and 
salazosulfapyridine were all considered the same treatment. A study conducted 
by Ito et al showed that pH-dependent ASA is significantly more effective on 
proctitis-type UC than time-dependent ASA [24]. However, the differences in the 
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effects of different types of ASA were not taken into consideration in our study. 
Third, the presence or absence of concomitant local treatment was not included in 
the criteria. Marteau et al has shown that, in mild to moderate UC including but 
not limited to proctitis-type UC, remission-induction rates were higher after 
treatment with a combination of oral ASA and suppository than after treatment 
with oral ASA alone [25,26]. In our study, the differences in 
remission-maintenance rates may have been caused by the presence or absence of 
concomitant use of drugs. Fourth, our study is a single-center retrospective study 
with a small sample size. The number of patients is not large enough to allow 
statistical analysis. For example, there were only four patients WEH whose dose 
was reduced. 
In conclusion, our study has shown that even in patients with clinical remission 
or EH, relapse was more likely to be prevented by keeping ASA doses unchanged 
than by reducing them. Thus, we recommend keeping the dosage unchanged as 
much as possible. The results of this study also raise the possibility of a difference 
in remission maintenance rates between patients with MES 0 and those with 
MES 1, suggesting that achievement of MES 0 could be a useful treatment goal. 
In the future, this issue, as well as possible risk(s) of relapse, should be 
investigated in multicenter, prospective studies. 
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FIGURE LEGENDS 
Figure 1. Flow chart to identify patients eligible for analyses. 
Figure 2. Comparison between the unchanged-ASA and reduced-ASA groups 
revealed a significant difference in remission-maintenance rates (P < 0.001). 
Figure 3. Comparison between the low dose of ASA (LD) and reduced-ASA 
groups revealed a significant difference in remission-maintenance rates (P < 
0.001). 
Figure 4. Comparison between the endoscopic healing (EH) and without 
endoscopic healing (WEH) groups revealed a significant difference in 
remission-maintenance rates (P = 0.020). 
Figure 5. Comparison between the endoscopic healing (EH) / unchanged-ASA 
and the EH / reduced-ASA groups revealed a significant difference in 
remission-maintenance rates (P = 0.042). 
Figure 6. Comparison between the Mayo endoscopic subscore (MES) 
0/unchanged-ASA and MES 0/reduced- ASA groups revealed no significant 
difference in remission-maintenance rates (P = 0.111). 
